FDA OKs Gene Therapy for Rare Mutation-Associated Vision Loss
December 19th 2017Officials with the FDA have approved voretigene neparvovec-rzyl (Luxturna, Spark Therapeutics), the first novel gene therapy for the treatment of an inherited form of vision loss in children and adults, according to an FDA press release.
Read More
FDA Officials Warn About MRI Dye
December 19th 2017FDA officials are now requiring a new patient medication guide, providing educational information that every patient will be asked to read before receiving a GBCA, and they are requiring manufacturers of GBCAs to conduct human and animal studies to further assess the safety of these contrast agents.
Read More